<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518517</url>
  </required_header>
  <id_info>
    <org_study_id>GRASPALL2009-06</org_study_id>
    <nct_id>NCT01518517</nct_id>
  </id_info>
  <brief_title>GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia</brief_title>
  <acronym>GRASPIVOTALL</acronym>
  <official_title>Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ERYtech Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ERYtech Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by
      toxicities including hypersensitivity. Clinical allergy is associated with inactivation of
      asparaginase by antibodies (A-Abs), which can also neutralize asparaginase without any
      clinical signs of hypersensitivity (silent inactivation). GRASPA improves pharmacokinetics,
      tolerability and maintain circulating asparaginase activity due to the protective barrier of
      the erythrocyte membrane.

      This study is run to confirm the benefit/risk profile of GRASPA at 150 IU/kg in combination
      with the COOPRALL regimen in adults and children patients with relapsed ALL, with or without
      known hypersensitivity to L-asparaginase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open, randomized international Phase 2/3 study will enrol patients with relapsed ALL.
      The co-primary endpoints were the duration of asparagine depletion &lt; 2µmol/L and the
      incidence of asparaginase hypersensitivity during induction. Key secondary endpoints are
      complete remission (CR), minimal residual disease (MRD), event free survival (EFS) and
      overall survival (OS).The study was powered to detect 3-fold difference in the incidence of
      allergic reactions between treatments. patients will be randomized to GRASPA or to Reference
      L-asparaginase. Patients with history of hypersensitivity to previous L-asparaginase
      treatment will be treated with GRASPA (exploratory arm)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy and toxicity combined</measure>
    <time_frame>1 month</time_frame>
    <description>efficacy assessed according mean duration of asparaginase activity / toxicity assessed according incidence of allergic reaction whatever the grade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular response rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of asparagine, aspartate, glutamine, glutamate and asparaginase</measure>
    <time_frame>0,1,3,6, 9 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific anti L-asparaginase antibodies</measure>
    <time_frame>0,10 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient with complete remission</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Acute Lymphoblastic Leukemia, in Relapse</condition>
  <arm_group>
    <arm_group_label>GRASPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).
GRASPA® administration takes place as below:
for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)
for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>reference L-asparaginase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).
•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).
NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)
•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRASPA</intervention_name>
    <description>one injection of GRASPA 150 IU/kg at each cycle of chemotherapy</description>
    <arm_group_label>GRASPA</arm_group_label>
    <other_name>ERY001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <description>3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy</description>
    <arm_group_label>reference L-asparaginase</arm_group_label>
    <other_name>KIDROLASE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient from 1 to 55 years old (Children and adolescents from 1 to 17 years/ Adults
             from 18 to 55 years)

          -  Patients with 1st ALL relapse, which could be either isolated bone marrow relapse, or
             combined (medullary and extra-medullary) relapse, or extra-medullary isolated relapse;
             or lymphoblastic lymphoma (excepted Burkitt lymphoma) OR Failure to ALL first line
             treatment (no complete remission obtained)

          -  Patient previously treated with free E.Coli L-asparaginase form or pegylated one

          -  Performance Status ≤ 2 (WHO score)

          -  Patient informed and consent provided (the 2 parents need to consent when children are
             below 18)

        Exclusion Criteria:

          -  ALL t(9;22) and/or BCR-ABL positive (Philadelphia chromosome positive)

          -  Patient with 2nd relapse and over

          -  Women of childbearing potential without effective contraception as well as pregnant or
             breast feeding women

          -  Patient unable to receive treatments used in global chemotherapy protocols, due to
             general or visceral conditions such as:Severe cardiac impairment (NYHA grade 3 or 4
             cardiomyopathy)/Serum creatinine 2 x ULN unless related to ALL /ALT or AST 5 x ULN
             unless related to ALL /Pancreatitis history /Other malignancy that ALL / Severe
             Infection, HIV positive, active hepatitis related to B or C virus infection / Trisomy
             21 / Other serious conditions according to investigator's opinion

          -  Known grade 4 allergic reaction to E.Coli L-asparaginase (according NCI-CTCAE, Version
             3.0)

          -  History of grade 3 transfusional incident

          -  Presence of specific anti-erythrocyte antibodies preventing from getting a compatible
             erythrocyte concentrate for the patient

          -  Patient under concomitant treatment likely to cause hemolysis

          -  Patient undergoing yellow fever vaccination

          -  Patient under phenytoin treatment

          -  Patient included in previous clinical study less than 6 weeks ago
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Bertand, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Des Enfants Reine Fabiola</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr de La Citadelle</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu D'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Jacques</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin Enfants</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille - Hop Jeanne de Flandres</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hematologie Oncologie Pediatrique</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Mere Enfant</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de L'Archet 2</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Hopital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Hopital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cancerologie de La Loire</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse Enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Brabois Enfants</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>relapse</keyword>
  <keyword>asparaginase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

